Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giacometti, A.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giacometti, A.
Right arrow Articles by Scalise, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 403-406
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates

Andrea Giacometti, Oscar Cirioni*, Francesco Barchiesi, Francesca Caselli and Giorgio Scalise

Institute of Infectious Diseases and Public Health, University of Ancona, Italy

The in-vitro activity of magainin II, indolicidin and ranalexin against 14 clinical isolates of eukaryotic microorganisms was evaluated. Antifungal susceptibility testing was performed by broth microdilution, and activity against Pneumocystis carinii and Cryptosporidium parvum was determined by inoculation on to cell monolayers. For yeasts, peptide MICs and MFCs ranged from 6.25 to >50 mg/L. Ranalexin showed the highest activity against Candidaspp., while magainin II demonstrated greatest anticryptococcal activity. The peptides suppressed the growth of P. carinii by >=50% and >=90% at 5 and 50 µ M, respectively, with the exception of indolicidin. Ranalexin, the most effective compound against C. parvum,suppressed its growth by >=40% at 50 µM.

* Corresponding address. Clinica Malattie Infettive -c/o Azienda Ospedaliera Umberto I, Piazza Cappelli, 1, I-60121 Ancona, Italy. Tel: +39-71-596-3467; Fax: +39-71-596-3468; E-mail: cmalin{at}popcsi.unian.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Y. Porat, K. Marynka, A. Tam, D. Steinberg, and A. Mor
Acyl-Substituted Dermaseptin S4 Derivatives with Improved Bactericidal Properties, Including on Oral Microflora
Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4153 - 4160.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Giacometti, O. Cirioni, F. Barchiesi, F. Ancarani, and G. Scalise
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture
J. Antimicrob. Chemother., April 1, 2000; 45(4): 453 - 456.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.